Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPulmonologyModa Health Cinqair IV Coverage & Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentModa HealthPolicy IC-273

    Cinqair (reslizumab) — Intravenous therapy coverage criteria

    Customize your policy alerts

    Sign up for Moda Health Policy IC-273 alerts

    Get alerted when Policy IC-273 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage and medical necessity criteria for intravenous reslizumab (Cinqair) as add-on maintenance treatment for severe eosinophilic asthma in adult members of Moda Health.

    Policy Summary
    PayerModa Health
    PolicyCinqair (reslizumab) — Intravenous therapy coverage criteria
    Policy CodePolicy IC-273
    Change TypeNo material change
    Effective Date
    Last ReviewOct 3, 2023
    Next Review DateOct 3, 2023
    Key ActionSubmit prior authorization demonstrating age ≥18, blood eosinophils ≥400 cells/µL, severe asthma with required background controller therapy, and dosing per policy (3 mg/kg IV q4w).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsauthorization length

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 mg/kg q4w
    recommended dosing
    >=400 cells/µLeosinophil threshold
    400 units/4wbilling limit
    >=18minimum age

    Coverage and Medical Necessity Criteria

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Age: Patient is at least 18 years of age>=18 years
    Eosinophilic phenotype: Blood eosinophils >= 400 cells/µL within 4 weeks of dosing>=400 cells/µL
    Severity and background therapy: Patient has severe asthma and is receiving both: medium-to-high dose inhaled corticosteroid AND an additional controller medication (e.g., long-acting beta agonist, leukotriene modifier)

    Components of severity may include symptoms throughout the day, nocturnal awakenings, frequent SABA use, FEV1 <60% predicted, frequent exacerbations

    Exacerbation history: Two or more exacerbations in the previous year requiring daily oral corticosteroids for at least 3 days in addition to maintenance therapy>=2 exacerbations/year
    Indication-specific dosing: Dose for severe eosinophilic asthma: 3 mg/kg IV every 4 weeks3 mg/kg q4w
    Exclusions: Not to be used in combination with other anti-IgE, anti-IL4, anti-IL5, or IgG2 lambda monoclonal antibodies (e.g., omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab) and not for other eosinophilic conditions (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome) or for relief of acute bronchospasm/status asthmaticus

    IV Renewal Criteria — Renewal provided when ALL of the following are met

    Renewal provided when ALL of the following are met

    Ongoing criteria: Patient continues to meet the universal and other indication-specific relevant criteria identified for initial approval
    Toxicity: Absence of unacceptable toxicity from the drug (examples include malignancy, parasitic/helminth infection, or anaphylaxis)

    Examples listed in policy

    Clinical improvement: Improvement in asthma symptoms or exacerbations as evidenced by one or more of the following: decreased use of systemic corticosteroids; two-fold or greater decrease in inhaled corticosteroid use for at least 3 days; fewer hospitalizations/ER/unscheduled visits; OR improvement in FEV1 from baseline

    At least one improvement metric required

    Reslizumab (Cinqair) must not be used in combination with other monoclonal biologic therapies targeting IgE, IL‑4, IL‑5, or IgG2 lambda. Examples listed in the policy include omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab. Concurrent use with these agents is an exclusion to coverage.

    Use of reslizumab for indications outside the policy-defined severe eosinophilic asthma population is not covered. The policy specifically excludes use for other eosinophilic disorders such as allergic bronchopulmonary aspergillosis/mycosis, Churg‑Strauss syndrome, and hypereosinophilic syndrome. In addition, reslizumab is not appropriate for relief of acute bronchospasm or status asthmaticus.

    Billing, Codes, and Quantity Limits

    Billing CPT/HCPCSHCPCSCovered
    J2786Injection, reslizumab, 1 mg
    NDCNDC
    59310-0610-xxCinqair 100 mg/10 mL single-use vial NDC
    Covered Diagnosis Codes (ICD-10)ICD-10Covered
    J45.50Severe persistent asthma, uncomplicated
    J82.81Eosinophilic pneumonia, NOS
    J82.82Acute eosinophilic pneumonia
    J82.83Eosinophilic asthma
    J82.89Other pulmonary eosinophilia, not elsewhere classified
    inv-08: Blood eosinophils 2D threshold value
    Blood eosinophil threshold>= 400 cells/µL (measured within 4 weeks of dosing)
    Phenotype requirementEosinophilic phenotype documented by peripheral blood eosinophils >= 400 cells/µL
    Timing of testEosinophil count must be obtained within 4 weeks prior to dosing
    inv-09: Quantity limit 2D Cinqair 100 mg vial
    Quantity limit (NDC)Cinqair 100 mg single-use vial: 4 vials every 28 days
    InterpretationMaximum of 400 mg (4 x 100 mg vials) supplied per 28-day period

    Provider Requirements and Documentation

    Prior Authorization

    Prior authorization required: eligibility and dosing

    Prior authorization is required and must demonstrate the patient is at least 18 years of age, has an eosinophilic phenotype with blood eosinophils ≥ 400 cells/µL within 4 weeks of dosing, meets severe asthma and exacerbation criteria (including ≥2 exacerbations in the prior year requiring daily oral corticosteroids for at least 3 days), and will receive dosing per policy (3 mg/kg IV every 4 weeks).

    • Age ≥ 18 years
    • Blood eosinophils ≥ 400 cells/µL within 4 weeks of dosing
    • Severe asthma and background controller therapy met
    • ≥2 exacerbations in previous year requiring daily oral corticosteroids for ≥3 days
    • Dose: 3 mg/kg IV every 4 weeks
    Step Therapy

    Background controller therapy required; no concurrent biologics

    Patient must be receiving maintenance medium-to-high dose inhaled corticosteroid AND an additional controller medication (for example a long-acting beta agonist or leukotriene modifier); concurrent use with other listed biologic agents is prohibited.

    Background and Indication

    Reslizumab (Cinqair) is an intravenous monoclonal antibody that targets interleukin‑5 (IL‑5) and is indicated as add‑on maintenance therapy for adults with severe eosinophilic asthma. The policy frames reslizumab as an anti‑IL‑5 biologic administered intravenously for this specific eosinophilic asthma population.

    Definitions

    inv-16: Severe asthma 2D clinical features
    Core definitionSevere asthma: asthma with features such as symptoms throughout the day, frequent nighttime awakenings, frequent SABA use, markedly limited activities, and more frequent/intense exacerbations compared with moderate asthma
    Objective lung functionFEV1 percent predicted < 60% may be a component supporting classification as severe
    Exacerbation frequencyExacerbations requiring oral systemic corticosteroids are generally more frequent and intense relative to moderate asthma
    Activity and symptom burdenExtremely limited normal activities and SABA use several times per day indicate severe disease
    Policy Summary
    PayerModa Health
    PolicyCinqair (reslizumab) — Intravenous therapy coverage criteria
    Policy CodePolicy IC-273
    Change TypeNo material change
    Effective Date
    Last ReviewOct 3, 2023
    Next Review DateOct 3, 2023
    Key ActionSubmit prior authorization demonstrating age ≥18, blood eosinophils ≥400 cells/µL, severe asthma with required background controller therapy, and dosing per policy (3 mg/kg IV q4w).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling, Codes, and Quantity LimitsProvider Requirements and DocumentationBackground and IndicationDefinitions
    Unit descriptionEach vial: Cinqair 100 mg/10 mL single-use vial
    inv-10: HCPCS billing limit
    HCPCS billing limit400 billable units every 4 weeks (J2786: 1 unit = 1 mg)
    Units-to-dose mappingPolicy dose for severe eosinophilic asthma: 3 mg/kg IV every 4 weeks (bill units accordingly)
    Billing codeJ2786 — Injection, reslizumab, 1 mg
    • Medium-to-high dose inhaled corticosteroid (ongoing)
    • Plus an additional controller medication (e.g., LABA, leukotriene modifier)
    • Do not use concurrently with other anti-IgE, anti-IL4, anti-IL5, or IgG2 lambda monoclonal antibodies
    Documentation Required

    Required clinical documentation to support request

    Submit documentation supporting patient age, blood eosinophil value within 4 weeks of dosing, evidence the patient meets severe asthma criteria (components listed in policy), history of ≥2 exacerbations in the prior year requiring daily oral corticosteroids for ≥3 days, and baseline clinical status measures.

    • Proof of age ≥ 18 years
    • Blood eosinophil lab result (≥ 400 cells/µL) obtained within 4 weeks of planned dosing
    • Clinical evidence of severe asthma (symptom pattern, nocturnal awakenings, frequent SABA use, FEV1, etc.)
    • Record of ≥2 exacerbations in previous year requiring systemic corticosteroids
    • Baseline metrics: systemic corticosteroid use, inhaled corticosteroid use, hospitalizations/ER/unscheduled visits, or FEV1
    Denial Risk

    Denial risk: excluded combinations and indications

    Requests for use in combination with other specified biologic agents (e.g., omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab) or for other eosinophilic conditions (allergic bronchopulmonary aspergillosis, Churg-Strauss, hypereosinophilic syndrome) or for acute bronchospasm/status asthmaticus will not be approved.

    • Combination therapy with other anti-IgE, anti-IL4, anti-IL5, or IgG2 lambda monoclonal antibodies is excluded
    • Use for other eosinophilic diseases (e.g., allergic bronchopulmonary aspergillosis, Churg-Strauss, hypereosinophilic syndrome) is excluded
    • Not for relief of acute bronchospasm or status asthmaticus